Management of Type 1 Diabetes with GLP-1 Receptor Agonists

Introduction to GLP-1 Receptor Agonists in Type 1 Diabetes

• Type 1 diabetics can safely take GLP-1 receptor agonists alongside insulin, with studies showing modest improvements in glycemic control, weight reduction, and decreased insulin requirements, though this remains an off-label use 1
• Clinical trials with liraglutide 1.8 mg daily in type 1 diabetes have demonstrated modest A1C reductions (approximately 0.4%), significant weight loss (about 5 kg), and reduced insulin requirements 1

Efficacy and Safety of GLP-1 Receptor Agonists

• GLP-1 RAs are not FDA-approved for type 1 diabetes 2
• The safety profile in type 1 diabetes appears similar to type 2 diabetes, with common side effects including gastrointestinal symptoms (nausea, vomiting) 3
• Unlike type 2 diabetes, type 1 diabetes patients are insulin-dependent and at higher risk of diabetic ketoacidosis, and insulin should never be discontinued when starting GLP-1 RAs 1

Patient Selection and Monitoring

• Consider GLP-1 RAs as adjunctive therapy in type 1 diabetes patients who have inadequate glycemic control despite optimized insulin therapy, would benefit from weight reduction, or have excessive postprandial glucose excursions 1
• Patients should be informed that GLP-1 RAs are not FDA-approved for type 1 diabetes 2

Insulin Adjustments and Medication Selection

• Improper insulin dose reduction when starting GLP-1 RAs could lead to hyperglycemia or DKA; conversely, failure to reduce insulin appropriately could increase hypoglycemia risk 1
• While multiple GLP-1 RAs exist, most studies in type 1 diabetes have been conducted with liraglutide 1